BR0313921A - Regime de reposição de estrogênio - Google Patents

Regime de reposição de estrogênio

Info

Publication number
BR0313921A
BR0313921A BR0313921-2A BR0313921A BR0313921A BR 0313921 A BR0313921 A BR 0313921A BR 0313921 A BR0313921 A BR 0313921A BR 0313921 A BR0313921 A BR 0313921A
Authority
BR
Brazil
Prior art keywords
estrogen replacement
estrogen
replacement regimen
regimen
dose estradiol
Prior art date
Application number
BR0313921-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Robert Casper
Gideon Kopernik
Zeev Shoham
Original Assignee
Gideon Kopernik
Zeev Shoham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gideon Kopernik, Zeev Shoham filed Critical Gideon Kopernik
Publication of BR0313921A publication Critical patent/BR0313921A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0313921-2A 2002-08-28 2003-08-28 Regime de reposição de estrogênio BR0313921A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40633102P 2002-08-28 2002-08-28
PCT/CA2003/001325 WO2004019954A1 (en) 2002-08-28 2003-08-28 Estrogen replacement regimen

Publications (1)

Publication Number Publication Date
BR0313921A true BR0313921A (pt) 2005-07-19

Family

ID=31978284

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0313921-2A BR0313921A (pt) 2002-08-28 2003-08-28 Regime de reposição de estrogênio

Country Status (25)

Country Link
US (1) US8946198B2 (https=)
EP (1) EP1539184B1 (https=)
JP (1) JP2005538150A (https=)
KR (1) KR20050059092A (https=)
CN (1) CN1678324A (https=)
AT (1) ATE345804T1 (https=)
AU (1) AU2003264203A1 (https=)
BR (1) BR0313921A (https=)
CA (1) CA2495330A1 (https=)
CY (1) CY1106019T1 (https=)
DE (1) DE60309895T2 (https=)
DK (1) DK1539184T3 (https=)
ES (1) ES2277139T3 (https=)
HR (1) HRP20050291A2 (https=)
IL (1) IL166585A0 (https=)
MX (1) MXPA05002294A (https=)
NO (1) NO20051545L (https=)
NZ (1) NZ538342A (https=)
PL (1) PL374762A1 (https=)
PT (1) PT1539184E (https=)
RS (1) RS20050184A (https=)
RU (1) RU2340345C2 (https=)
UA (1) UA82851C2 (https=)
WO (1) WO2004019954A1 (https=)
ZA (1) ZA200501274B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
DE102009007771B4 (de) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MX2016011801A (es) * 2014-03-12 2017-07-14 Warner Chilcott Co Llc Crema de estradiol de dosis baja.
EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
CR20180042A (es) 2015-06-18 2018-05-03 Mithra Pharmaceuticals S A Unidad de dosificación orodispersable que contiene un componente estetrol.
DK3701944T3 (da) 2015-06-18 2022-03-14 Estetra Srl Oro-dispergerbar doseringsenhed indeholdende en estetrolkomponent
LT3310346T (lt) 2015-06-18 2021-06-10 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
AU2016284459B2 (en) 2015-06-22 2021-12-23 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
CN111989105B (zh) 2018-04-19 2024-07-19 埃斯特拉私人有限责任公司 化合物以及它们在缓解绝经相关症状中的用途
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
EP0303306B1 (en) * 1987-08-08 1993-03-10 Akzo N.V. Contraceptive implant
US4900734A (en) * 1987-08-27 1990-02-13 Maxson Wayne S Novel pharmaceutical composition containing estradiol and progesterone for oral administration
US5108995A (en) * 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
US5256421A (en) * 1987-09-24 1993-10-26 Jencap Research Ltd. Hormone preparation and method
US5422119A (en) * 1987-09-24 1995-06-06 Jencap Research Ltd. Transdermal hormone replacement therapy
US5276022A (en) * 1987-09-24 1994-01-04 Jencap Research Ltd. Hormone preparation and method
DE3888269T2 (de) * 1987-09-24 1994-07-07 Jencap Research Ltd Hormon-Zusammensetzung und -Anwendung.
US5382873A (en) * 1991-12-04 1995-01-17 U.S. Philips Corporation High-pressure discharge lamp with incandescing metal droplets
US5521166A (en) * 1994-12-19 1996-05-28 Ortho Pharmaceitical Corporation Antiprogestin cyclophasic hormonal regimen
DE19513662A1 (de) * 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
CN1188189C (zh) * 1995-06-07 2005-02-09 奥瑟－麦内尔制药公司 基质层含有17－脱乙酰基诺孕酯的经皮贴片及基质的用途
US6506390B2 (en) * 1996-06-25 2003-01-14 Akzo Nobel Progestogen-anti-progestogen regimens
CA2267743C (en) * 1999-03-30 2011-07-26 Robert F. Casper Low dose estrogen interrupted hormone replacement therapy
US6653298B2 (en) * 2000-01-14 2003-11-25 Sterix Limited Composition
DE10100911A1 (de) * 2001-01-11 2002-08-01 Schering Ag Verfahren zur Hormonersatztherapie und dessen Darreichungsform

Also Published As

Publication number Publication date
AU2003264203A1 (en) 2004-03-19
MXPA05002294A (es) 2005-09-12
JP2005538150A (ja) 2005-12-15
NZ538342A (en) 2007-08-31
RS20050184A (sr) 2007-11-15
DE60309895D1 (de) 2007-01-04
ATE345804T1 (de) 2006-12-15
US8946198B2 (en) 2015-02-03
HRP20050291A2 (en) 2005-10-31
WO2004019954A1 (en) 2004-03-11
EP1539184B1 (en) 2006-11-22
DE60309895T2 (de) 2007-10-18
UA82851C2 (en) 2008-05-26
PT1539184E (pt) 2007-02-28
RU2340345C2 (ru) 2008-12-10
US20060089337A1 (en) 2006-04-27
ES2277139T3 (es) 2007-07-01
NO20051545L (no) 2005-03-23
RU2005108977A (ru) 2005-10-10
IL166585A0 (en) 2006-01-15
DK1539184T3 (da) 2007-03-19
CN1678324A (zh) 2005-10-05
CY1106019T1 (el) 2011-04-06
EP1539184A1 (en) 2005-06-15
CA2495330A1 (en) 2004-03-11
ZA200501274B (en) 2006-08-30
KR20050059092A (ko) 2005-06-17
PL374762A1 (en) 2005-10-31

Similar Documents

Publication Publication Date Title
BR0313921A (pt) Regime de reposição de estrogênio
BRPI0203172B8 (pt) composição farmacêutica para acondroplasia
BR0015026A (pt) Indóis substituìdos para a modulação da atividade de nfkb
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
CR7611A (es) Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
BR9909138A (pt) Combinação para o tratamento de dependência de álcool e drogas contendo um antagonista de opióide e um modulador de complexo receptor de nmda
SI1526856T1 (sl) Farmacevtski sestavek, ki obsega estetrolne derivate za uporabo pri zdravljenju raka
PT1409021E (pt) Formulação compreendendo fulvestrant
ECSP066865A (es) Dispositivo de distribución de fármacos visible por rayos x
BR0310085A (pt) Terapia de substituição de hormÈnio
AR020832A1 (es) Procedimiento para la preparacion de una composicion de alta pureza de (7alfa, 17alfa)-17-hidroxi-7-metil-19-nor-17-pregn-5-(10)-en-20-in-3-ona
ECSP066291A (es) Sistemas emulsionantes que contienen derivados de azetidina
AR043013A1 (es) Composicion farmaceutica destinada al tratamiento de la endometriosis
BR0309032A (pt) Método para tratar sintomas vasomotores, a menopausa, deficiências hormonais em um paciente, e para tratar um paciente que sofre de sintomas vasomotores
BRPI0407410A (pt) método para o tratamento de hipotireoidismo
BR0311184A (pt) Terapia de reposição de hormÈnio
BRPI0505090A (pt) composição de toner
TW200612962A (en) Estriol and estetrol prodrugs
BR0308968A (pt) terapia de reposição hormonal
PL1635843T3 (pl) Hormonalna terapia zastępcza i leczenie depresji obejmujące dienogest
BRPI0415226A (pt) regime de tratamento de cáncer de mama
BRPI0606724A2 (pt) preparação farmacêutica para contracepção
DK1343508T3 (da) Anvendelse af et østrogen til fremstilling af en sammensætning, der indeholder østrogen, til behandling af atrofisk vaginitis

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2069 DE 31/08/2010.